Jayson Slotnik, JD, MPH
Health Policy Strategies, Inc.
Jayson S. Slotnik is a principal and founding member of Health Policy Strategies, Inc., a Washington, DC based consulting firm representing innovative biotech, pharmaceutical, device and diagnostic companies. Mr. Slotnik specializes in, and counsels clients on, the impact that Medicare and Medicaid coverage, payment, reimbursement, coding and government policies have on commercial success. He also has experience as a healthcare strategist with demonstrated success in developing and implementing both pre- and post-launch strategies, as well as life cycle management tools for pharmaceutical, biotechnology, diagnostic and device manufacturers.
Prior to establishing Health Policy Strategies, Inc., Mr. Slotnik served as Vice President of Reimbursement and Innovation Strategies for United BioSource Corporation (UBC). There, he was responsible for developing technology-related marketing and sales strategies for current internal and new external customers in the branded specialty pharmaceutical space. Mr. Slotnik partnered with the business development team to market technology strategies to over 20 branded specialty manufacturers. In addition, he maintained his policy practice, which helped distinguish UBC’s market access technology, as well as affording his clients the ability to have the business drive the policy and not the reverse.
Before joining UBC, Mr. Slotnik practiced law at two prominent Washington, DC law firms where he counseled clients on many complex healthcare regulatory and legal issues related to coverage, coding and reimbursement. Before returning to private practice, he served as the initial director of Medicare Reimbursement and Economic Policy at the Biotechnology Industry Organization (BIO), the industry’s leading advocacy group. Mr. Slotnik served as the liaison between BIO and Congress, CMS, and other federal agencies to implement market access policies that stimulate and reward innovation while maintaining appropriate patient access to cutting edge therapies.
Mr. Slotnik serves on the editorial boards for Value-Based Cancer Care and Specialty Pharmacy Times. He speaks regularly at various healthcare reform and market-access conferences.
Mr. Slotnik received a Bachelor of Arts degree in English from the University of Rochester, his Masters in Public Health with a concentration in Epidemiology and Biostatistics from George Washington University, and his Juris Doctor degree in Health Law from the University of Maryland School of Law.